Jul 29, 2019

Pfizer merging off-patent drugs business with Mylan

Marisa Fernandez

Pfizer will merge its off-patent drugs business with generic maker Mylan to create a giant global seller of lower-priced drugs, the Wall Street Journal first reported.

Why it matters: The world's largest drug maker's deal with Mylan brings together two businesses that have experienced slowed sales since former big sellers lost patent protection.

Details on the agreement:

  • Pfizer shareholders would own 57% of the new company and Mylan shareholders would own 43%, Mylan confirmed to Reuters Monday.
  • The combined company would be based in the U.S. and current Mylan Chief Executive Heather Bresch would leave.
  • The companies hope for a boost in business on key drugs that lost patent protection: Pfizer has Lipitor cholesterol pills and Viagra, and Mylan has the EpiPen emergency allergy shot.

Go deeper

Caitlin Owens

How Democrats want to limit drug prices

Illustration: Rebecca Zisser/Axios

The Democratic presidential candidates' plans to lower drug prices are much more aggressive than what the party has supported in the past.

Between the lines: There are big differences among the candidates' platforms, but the entire debate has shifted to the left.

Go deeperArrowAug 8, 2019
Caitlin Owens

Hospitals' drug bills are likely going up in 2020

Health systems should expect a 4.57% increase in their drug spending in 2020, according to a new analysis by Vizient, a health care performance improvement company.

Why it matters: Some of the most expensive drugs on the market are administered in hospitals and doctors' offices, and they're folded into a patient's overall hospital bill.

Go deeperArrowAug 7, 2019
Caitlin Owens

HHS announces pathways for prescription drug importation

HHS Secretary Alex Azar. Photo: Alex Wong/Getty Images

The Trump administration announced Wednesday that it is taking steps to open the door for prescription drugs to be imported into the U.S. from other countries.

The big picture: Drug importation has long been a policy idea championed mostly by Democrats, but there are plenty of reasons to be skeptical that it'll have much of an impact on drug prices — beginning with other countries' lack of enthusiasm for sending us their drugs.

Go deeper: Importing prescription drugs from Canada is tougher than it sounds

Keep ReadingArrowJul 31, 2019